Equine

Solutions that help maintain and improve the health and welfare of horses.

Our Story

Today, we develop breakthrough medicines, vaccines and technology that improve the health and well-being of animals worldwide.

Contact Us

For information about Merck Animal Health’s products and services including the reporting of an adverse event or product quality complaint with a specific Merck Animal Health product

Research and Innovation

At Merck Animal Health, our scientists and experts are constantly searching for ways to advance the state of veterinary medicine and animal health.

Homepage

Merck Animal Health – Information on veterinary products, technologies and veterinary services that truly advance animal healthcare.

News Releases

Mexico’s SADER Approves Merck Animal Health’s EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)

Veterinarians and cattle producers in Mexico have access to a new tool to protect cattle from New World Screwworm, helping to safeguard Mexico’s beef supply RAHWAY, N.J., November 4, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J

Featured Stories

Enhancing Multivalent Inactivated Vaccines for Long-Living Birds

Poultry is a cornerstone of global food security. It provides affordable, high-quality protein in the form of both meat and eggs, feeding billions of people worldwide.

News Releases

New Data from Merck Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves

Vaccinated calves showed fewer lung lesions and achieved a significantly higher body weight than unvaccinated calves Rahway, N.J., October 23, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the presentation of new data

News Releases

Merck Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple

News Releases

Merck Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program

RAHWAY, N.J., Sept. 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded.

News Releases

New Study Confirms Rapid Action of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets for the Treatment of Equine Protozoal Myeloencephalitis (EPM)

Diclazuril reaches therapeutic levels within 12 hours, reinforcing the drug as a first-line EPM treatment option RAHWAY, N.J., September 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the results of a new

News Releases

Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

RAHWAY, N.J., September 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate